These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 9160648)

  • 21. Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression.
    Maes M; Vandoolaeghe E; Desnyder R
    J Affect Disord; 1996 Dec; 41(3):201-10. PubMed ID: 8988452
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Olanzapine in the treatment of resistant depression.
    Caetano D; Caetano SC
    Aust N Z J Psychiatry; 2005; 39(1-2):108-9. PubMed ID: 15660713
    [No Abstract]   [Full Text] [Related]  

  • 23. Lower gastrointestinal bleeding and paroxetine use: two case reports.
    Blasco-Fontecilla H; de Leon J
    Psychosomatics; 2012; 53(2):184-7. PubMed ID: 22424167
    [No Abstract]   [Full Text] [Related]  

  • 24. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder.
    Pollack MH; Lepola U; Koponen H; Simon NM; Worthington JJ; Emilien G; Tzanis E; Salinas E; Whitaker T; Gao B
    Depress Anxiety; 2007; 24(1):1-14. PubMed ID: 16894619
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Paroxetine augmentation with risperidone in therapy-resistant depression].
    Knopf U; Hubrich-Ungureanu P; Thome J
    Psychiatr Prax; 2001 Nov; 28(8):405-6. PubMed ID: 11721229
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Venlafaxine: loss of antidepressant effect and its management.
    Sharma V
    J Clin Psychiatry; 1998 Jul; 59(7):381-2. PubMed ID: 9714268
    [No Abstract]   [Full Text] [Related]  

  • 27. Combined antidepressant treatment: a risk factor for switching in bipolar patients.
    Gabbay V; O'Dowd MA; Asnis GM
    J Clin Psychiatry; 2002 Apr; 63(4):367; author reply 367-8. PubMed ID: 12000212
    [No Abstract]   [Full Text] [Related]  

  • 28. Six-month paroxetine treatment of premenstrual dysphoric disorder: continuous versus intermittent treatment protocols.
    Wu KY; Liu CY; Hsiao MC
    Psychiatry Clin Neurosci; 2008 Feb; 62(1):109-14. PubMed ID: 18289149
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The modern pharmacopoeia: a return to depressive realism?
    Goldberg JF
    Bipolar Disord; 2008 Dec; 10(8):969-72. PubMed ID: 19594511
    [No Abstract]   [Full Text] [Related]  

  • 30. Bupropion-induced hypomania in a patient with unipolar depression.
    Hussain H; Butt MA
    Aust N Z J Psychiatry; 2008 Aug; 42(8):746. PubMed ID: 18622783
    [No Abstract]   [Full Text] [Related]  

  • 31. Does subclinical hypothyroidism predispose to tricyclic-induced rapid mood cycles?
    Extein I; Pottash AL; Gold MS
    J Clin Psychiatry; 1982 Jul; 43(7):290-1. PubMed ID: 6806254
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pindolol potentiates the panicolytic effect of paroxetine in the elevated T-maze.
    Sela VR; Roncon CM; Zangrossi H; Graeff FG; Audi EA
    Life Sci; 2010 Sep; 87(13-14):445-50. PubMed ID: 20816996
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relapse prevention by means of paroxetine in ECT-treated patients with major depression: a comparison with imipramine and placebo in medium-term continuation therapy.
    Lauritzen L; Odgaard K; Clemmesen L; Lunde M; Ohrström J; Black C; Bech P
    Acta Psychiatr Scand; 1996 Oct; 94(4):241-51. PubMed ID: 8911559
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adverse effects of pindolol augmentation in patients with bipolar depression.
    Yatham LN; Lint D; Lam RW; Zis AP
    J Clin Psychopharmacol; 1999 Aug; 19(4):383-4. PubMed ID: 10440473
    [No Abstract]   [Full Text] [Related]  

  • 35. Paroxetine and akathisia.
    Adler LA; Angrist BM
    Biol Psychiatry; 1995 Mar; 37(5):336-7. PubMed ID: 7748986
    [No Abstract]   [Full Text] [Related]  

  • 36. How long should pindolol be associated with paroxetine to improve the antidepressant response?
    Zanardi R; Artigas F; Franchini L; Sforzini L; Gasperini M; Smeraldi E; Perez J
    J Clin Psychopharmacol; 1997 Dec; 17(6):446-50. PubMed ID: 9408806
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Possible neuroleptic malignant syndrome related to concomitant treatment with paroxetine and alprazolam.
    Tanii H; Ichihashi K; Inoue K; Fujita K; Okazaki Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Aug; 30(6):1176-8. PubMed ID: 16720068
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A case of serial nightmares and oneiroid state under paroxetine for senile depression.
    Kobayashi T; Yamauchi M
    Psychogeriatrics; 2012 Mar; 12(1):54-7. PubMed ID: 22416829
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neurochemistry and paroxetine response in major depression.
    Goodnick PJ; Henry J; Kumar A
    Biol Psychiatry; 1995 Mar; 37(6):417-9. PubMed ID: 7772652
    [No Abstract]   [Full Text] [Related]  

  • 40. A case of rapid mood cycling with estrogen: implications for therapy.
    Oppenheim G
    J Clin Psychiatry; 1984 Jan; 45(1):34-5. PubMed ID: 6141158
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.